Table 1.
Vaginal Leukocytes and Activation Markers in the Follicular and Luteal Phases of a Control (No Treatment) Cycle Versus 12 Weeks Post-Depot Medroxyprogesterone Acetate Treatment
| |
Median cell count (cells/mm2) (25th, 75th percentile, quantile)a |
Wilcoxon signed rank p value |
|||
|---|---|---|---|---|---|
| Phenotype of immune cells in the vaginal epithelium | Follicular phase | Luteal phase | DMPA treatment | Follicular vs. DMPA | Luteal vs. DMPA |
| CD45 | 70.6 (37.5, 159.6) | 73.5 (31.7, 120.3) | 156.9 (112.4, 277.3) | 0.03 | 0.22 |
| CD3 | 40.0 (23.8, 60.0) | 45.9 (11.3, 70.7) | 76.5 (47.8, 117.9) | 0.08 | 0.04 |
| CD4b | 0 (0, 0) | 0 (max 11.6) | 0 (max 9.3) | NA | NA |
| CD8 | 28.1 (18.4, 44.9) | 29.1 (9.3, 54.4) | 52.6 (40.9, 85.6) | 0.15 | 0.01 |
| CD1a | 26.4 (16.7, 60.9) | 27.6 (17.8, 41.7) | 33.9 (26.0, 54.9) | 0.13 | >0.99 |
| CD68 | 1.5 (0, 5.1) | 3.3 (0, 5.4) | 7.2 (3.9, 22.0) | 0.01 | 0.07 |
| CCR5b | 0.2 (0, 0.5) | 0.2 (0, 0.6) | 0.8 (0, 1.2) | 0.09 | 0.05 |
| HLA-DR | 97.4(81.0, 120.0) | 82.4 (46.5, 102.6) | 113.9 (85.1, 184.3) | 0.02 | 0.35 |
a
Data are not normally distributed and are thus expressed as median (25th percentile, 75th percentile).
b
CD4 and CCR5-positive cells counted in lamina propria.
Bold numbers indicate statistically significant differences.
DMPA, depot medroxyprogesterone acetate.